Anlotinib and chemotherapy for advanced lung cancer with smarca4 deficiency
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a targeted drug (anlotinib) with chemotherapy for people with a specific type of lung cancer that has a genetic change called SMARCA4 deficiency. The goal is to see if this combination can shrink tumors and help people live longer without the cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung cancer is stage IIIB or IV and cannot be removed with surgery.
- Your tumor has a specific genetic change called SMARCA4 deficiency (found through a special test).
- You have not had any previous treatment for your lung cancer.
- You are in fairly good health (able to take care of yourself and up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (QL1706) with standard chemotherapy for people whose lung cancer has a specific genetic change (SMARCA4 deficiency). The goal is to see if this combination can shrink tumors and improve outcomes for this particular group of patients.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This trial studies a combination therapy (called ABCP) as the first treatment for advanced non-squamous lung cancer that has a specific genetic change called SMARCA4. The goal is to see if this treatment is safe and works well for people who have not had prior systemic therapy.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
This study tests a new combination of two drugs (QL1706 and anlotinib) for people with advanced small cell lung cancer or squamous cell lung cancer who have already tried at least two earlier treatments. The goal is to see if this combination can help control the cancer when other options have stopped working.
Hear when a new SMARCA4-Deficient Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.